At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMMX Immix Biopharma, Inc.
Not Yet Opened 11-04 16:00:00 EST
7.97
+0.26
+3.37%
盘后7.97
+0.000.00%
19:30 EST
High8.16Low7.56Vol1.25M
Open7.93D1 Closing7.71Amplitude7.78%
Mkt Cap662.14MTradable Cap560.51MTotal Shares83.08M
T/O9.83MT/O Rate1.78%Tradable Shares70.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immix Biopharma to Present NXC-201 Trial Data from 45 Patients at ASH 2026
Reuters  ·  11-04 22:17
Immix Biopharma to Present NXC-201 Trial Data from 45 Patients at ASH 2026
Immix Biopharma’s Nxc-201 Nexicart-2 Interim Clinical Trial Results Selected for Oral Presentation at Ash 2026
THOMSON REUTERS  ·  11-04 22:15
Immix Biopharma’s Nxc-201 Nexicart-2 Interim Clinical Trial Results Selected for Oral Presentation at Ash 2026
Immix Biopharma price target lowered to $23 from $26 at Mizuho
TIPRANKS  ·  10-29
Immix Biopharma price target lowered to $23 from $26 at Mizuho
Immix Biopharma to Present at J.P. Morgan Healthcare Conference
Reuters  ·  10-05
Immix Biopharma to Present at J.P. Morgan Healthcare Conference
Immix Biopharma Closes $125 Million Stock Offering
MT Newswires Live  ·  10-01
Immix Biopharma Closes $125 Million Stock Offering
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
THOMSON REUTERS  ·  10-01
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB
Reuters  ·  09-30
US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB
Immix Biopharma, Inc. : Needham Raises Target Price to $30
THOMSON REUTERS  ·  09-30
Immix Biopharma, Inc. : Needham Raises Target Price to $30
Immix Biopharma is Maintained at Buy by Needham
Dow Jones  ·  09-30
Immix Biopharma is Maintained at Buy by Needham
Immix Biopharma price target raised to $30 from $27 at BofA
TIPRANKS  ·  09-29
Immix Biopharma price target raised to $30 from $27 at BofA
Immix Biopharma prices 11.36M share registered offering at $11.00
TIPRANKS  ·  09-29
Immix Biopharma prices 11.36M share registered offering at $11.00
Immix Biopharma Prices 11,363,637-Share Offering at USD 11.00 Per Share for USD 125 Million Gross Proceeds
Reuters  ·  09-29
Immix Biopharma Prices 11,363,637-Share Offering at USD 11.00 Per Share for USD 125 Million Gross Proceeds
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
THOMSON REUTERS  ·  09-29
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma, - Prices 11,363,637 Shares at $11 Per Share
THOMSON REUTERS  ·  09-29
Immix Biopharma, - Prices 11,363,637 Shares at $11 Per Share
Immix Biopharma, - Net Proceeds to Fund Nxc-201 Development, Working Capital, Corporate Purposes
THOMSON REUTERS  ·  09-29
Immix Biopharma, - Net Proceeds to Fund Nxc-201 Development, Working Capital, Corporate Purposes
Immix Biopharma Says Nexicart-2 Interim Data Show 89% Complete Response Rate for NXC-201 in Relapsed/refractory AL Amyloidosis
Reuters  ·  09-29
Immix Biopharma Says Nexicart-2 Interim Data Show 89% Complete Response Rate for NXC-201 in Relapsed/refractory AL Amyloidosis
Immix Biopharma, - Nexicart-2 Final Readout and Bla Submission Planned for Mid-2027
THOMSON REUTERS  ·  09-29
Immix Biopharma, - Nexicart-2 Final Readout and Bla Submission Planned for Mid-2027
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All Nexicart-2 Patients, with Mrd-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis
THOMSON REUTERS  ·  09-29
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All Nexicart-2 Patients, with Mrd-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis
Immix Biopharma, - 100% of New Nexicart-2 Patients in Complete Response or Mrd-Negative
THOMSON REUTERS  ·  09-29
Immix Biopharma, - 100% of New Nexicart-2 Patients in Complete Response or Mrd-Negative
Immix Biopharma, Inc. : Mizuho Raises Target Price to $26 from $15
THOMSON REUTERS  ·  09-16
Immix Biopharma, Inc. : Mizuho Raises Target Price to $26 from $15

Introduction

Company Name.
Immix Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Issue price:
--